8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
May 4, 2026·SEC
Aura Biosciences, Inc.(AURA)Earnings, Financials & Key Ratios
AURA•NASDAQ
$7.00
Price updated Jun 27, 2026
AboutAura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA-$112M-17.7%
- Net Income-$106M-22.2%
- EPS (Diluted)-1.76-0.6%
- ROE-73.52%-59.8%
AURA Price & Volume
Aura Biosciences, Inc. (AURA) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Cash Runway Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Insufficient clinical cash runway
"Aura Biosciences remains in a high-risk, pre-revenue clinical stage, with its valuation heavily dependent on the successful execution of the Phase 3 CoMpass trial for its VDC platform. While the company maintains a conservative capital structure with a debt-to-equity ratio of 0.16, the persistent quarterly operating loss of $34.9 million necessitates ongoing external financing. Investors should monitor the company's ability to manage its $84.8 million cash position against escalating R&D expenditures before further dilutive events occur."
Verdict Logic
the company's current cash position of $84.8 million appears insufficient to cover the $34.9 million quarterly operating loss, suggesting a high probability of near-term dilutive financing.
AURA Growth Metrics
Aura Biosciences, Inc. (AURA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-18.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM6.84%
Return on Capital
10 Years-56.44%
5 Years-45.76%
3 Years-51.64%
Last Year-70.8%
AURA Recent Earnings
Aura Biosciences, Inc. (AURA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.50-25.0%
$0.40
Rev
—
—
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.37+14.0%
$0.43
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.40+13.0%
$0.46
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.47+4.1%
$0.49
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.50vs $0.40-25.0% | — |
| Q2 2026 | Mar 30, 2026 | $0.37vs $0.43+14.0% | — |
| Q4 2025 | Nov 13, 2025 | $0.40vs $0.46+13.0% | — |
| Q3 2025 | Aug 13, 2025 | $0.47vs $0.49+4.1% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Aura Biosciences, Inc. (AURA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.00 | $449.4M | -3.98 | — | — | -73.52% | — | |
| $9.84 | $2.15B | -6.93 | -18.67% | -558.24% | -64.55% | — | |
| $3.25 | $354.88M | -1.62 | — | — | -70.79% | — | |
| $4.36 | $96.26M | -0.66 | -72.22% | — | — | — | |
| $11.63 | $960.32M | -3.79 | — | — | -102.69% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — |
Compare AURA vs Peers
Aura Biosciences, Inc. (AURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AURA SEC Filings & Documents
Aura Biosciences, Inc. (AURA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when AURA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AURA Frequently Asked Questions
Aura Biosciences, Inc. (AURA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is AURA profitable?
Aura Biosciences, Inc. (AURA) reported a net loss of $112.4M for fiscal year 2025.
Dividend & Returns
What is AURA's return on equity?
Aura Biosciences, Inc. (AURA) has a return on equity (ROE) of -73.5%. Negative ROE indicates the company is unprofitable.
What is Aura Biosciences, Inc.'s free cash flow?
Aura Biosciences, Inc. (AURA) had negative free cash flow of $91.6M in fiscal year 2025, likely due to heavy capital investments.